培美曲塞二线治疗老年晚期非小细胞肺癌的临床观察  

Effect of pemetrexed in the second line treatment elderly patients with advanced non-small cell lung cancer

作　　者：龚志敏[1,2] 孙秋实[1] 杜珂[1] 

机构地区：[1]襄阳市中心医院肿瘤科,湖北襄阳441021 [2]武汉大学医学院研究生院,湖北武汉430073

出　　处：《现代肿瘤医学》2012年第10期2075-2077,共3页Journal of Modern Oncology

摘　　要：目的:探讨培美曲塞二线治疗老年晚期非小细胞肺癌的疗效及不良反应。方法:老年晚期非小细胞肺癌患者34例,采用培美曲塞500 mg/m2,静脉滴注,第1天;21d为1周期,至少2周期后评价疗效。结果:有效率(RR)为14.7%,中位TTP 3.2个月,中位生存期7.9个月。主要毒副反应为骨髓抑制及消化道反应。结论:培美曲塞二线治疗老年晚期非小细胞肺癌的近期疗效较好,且患者耐受性好,值得临床推广。Objective：To evaluate the efficacy and the side-effects of pemetrexed as second-line treatment of elderly patients with advanced non-small cell lung cancer.Methods： Thirty-four elderly patients with advanced non-small cell lung cancer accepted the chemotherapy of pemetrexed 500mg/m2 on day 1.Three weeks as a circle.The effic acy and the side-effects were evaluated at least after two circles.Results： The total effective rate was 14.7%.The median time to progress was 3.2 months and the median survival was 7.9 months.The main side-effects were myelosuppression,nausea and vomiting.Conclusion： Pemetrexed in the second line of treatment of elderly patients with advanced non-small cell lung cancer is effective and with low side-effects.

关 键 词：非小细胞肺癌 化疗 培美曲塞 

分 类 号：R734.2[医药卫生—肿瘤]